NMN vs NR: Which NAD+ Precursor Has the Better Evidence?

The one-sentence version

No randomized trial has ever compared NMN and NR head to head for any outcome. Every "NMN is better" or "NR is better" claim you will read is an argument from mechanism, from a single small study, or from whoever is selling. What can be said is narrower and more useful: NR has the longer and better-documented safety record, NMN has produced the more interesting metabolic signals, and neither has demonstrated an effect on aging.

What they are

Both are precursors to NAD+, the coenzyme every cell uses for energy metabolism and DNA repair, and which declines with age. You cannot usefully swallow NAD+ itself — it is broken down before it reaches your cells — so oral products sell a precursor that survives the trip and is converted inside the body.

• •NR — nicotinamide riboside. One enzymatic step further from NAD+.
• •NMN — nicotinamide mononucleotide. One step closer, which is the entire basis of the "more direct" marketing claim.

Being one step closer in a diagram is not evidence of anything. It is the reason the argument exists, not the resolution of it.

The case for NR: the deeper safety file

NR has been through more, and longer, human studies.

• •Chronic supplementation was well tolerated and reliably elevated NAD+ in healthy middle-aged and older adults¹.
• •A randomized, double-blind, placebo-controlled trial of a commercial NR product examined safety and metabolism over long-term administration in healthy overweight adults².
• •A randomized placebo-controlled trial in obese men measured safety, insulin sensitivity and lipid-mobilizing effects³.
• •It has been taken into disease populations — a phase I trial in Parkinson's disease⁴ and a safety and tolerability study in heart failure with reduced ejection fraction⁵.

That breadth matters for a product people take daily for years. It is a safety argument, not an efficacy one.

The case for NMN: the more interesting signals

NMN has fewer trials, and two of them found something.

• •NMN increased muscle insulin sensitivity in prediabetic women⁶ — a real, mechanistically coherent metabolic result.
• •It improved aerobic capacity in amateur runners⁷.
• •A 2023 trial examined its efficacy and safety in middle-aged adults⁸.

Both positive findings are in specific, narrow populations, and neither is an aging outcome.

Where both of them land

They raise NAD+. That is not in dispute for either compound.

The functional evidence is weak. A 2025 systematic review and meta-analysis of NMN and NR together found no significant improvement in skeletal muscle mass or function in older adults⁹. The NICE randomized clinical trial of nicotinamide riboside in peripheral artery disease did not find the walking-performance benefit it was designed to detect¹⁰.

And the overall verdict. The 2026 PRISMA-guided systematic review, covering 113 studies including 33 human intervention trials, concluded that oral precursors consistently raise NAD+ and are well tolerated while effects on functional, metabolic and vascular outcomes were "heterogeneous and often null," with clinical effectiveness for anti-aging inconclusive¹¹.

So which should you buy?

If you have decided to take one, the honest decision rule is short:

• •Want the deepest safety record? NR. More trials, longer administration, more populations.
• •Want the compound with the most interesting metabolic findings? NMN, understanding those are two small studies in specific groups.
• •Want the one proven to slow aging? Neither. That trial does not exist for either compound.

And a note on price that applies to both. These are supplements, and a prescription NAD+ product is not a better version of them — one graded provider prices a prescription NAD+ tablet beside its injection at several times what a jar of either precursor costs, against the same human evidence. Where each route has actually been tested is in NAD+ injections vs IV vs oral, and how these two sit against every other popular pill is in the best longevity supplements, rated by evidence.